T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020
T2 Biosystems (NASDAQ:TTOO) has announced that it will report its third-quarter 2020 financial results after the market closes on November 4, 2020. Following the release, company management will host a conference call at 4:30 p.m. ET. Investors can listen to the live and archived webcast on T2 Biosystems' website or by dialing the provided numbers. The company is recognized for its rapid detection of sepsis-causing pathogens and has a pipeline of products, including the T2Dx Instrument and various diagnostic panels.
- T2 Biosystems is a leader in rapid pathogen detection, positioning itself favorably in a critical healthcare market.
- The company has a robust product lineup, including T2Candida and T2Bacteria panels, enhancing its market presence.
- None.
LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the third quarter of 2020 after market close on Wednesday, November 4, 2020. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 877-407-9208 (U.S.) or 201-493-6784 (International) five to ten minutes prior to the start time.
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
FAQ
When will T2 Biosystems report its Q3 2020 earnings?
What time is the T2 Biosystems Q3 earnings conference call?
How can I access the T2 Biosystems earnings call?
What products does T2 Biosystems offer?
